DocumentNot applicableNotice

Mycophenolate Mofetil Mmf Containing Products Risk Of Pregnancy Loss And Congenital Malformations Extension Of The Post Treatment Contraception Period From 6 Weeks To 6 Months For

South African Health Products Regulatory Authority

Official source

Source domain: sahpra.org.za

Collected on 22 October 2026

Always confirm details on the official source before acting.

What this means

SAHPRA's safety communication reports that the post-treatment contraception period for women of childbearing potential taking mycophenolate mofetil (MMF)-containing products is extended from 6 weeks to 6 months, because of the risk of pregnancy loss and congenital malformations. It is directed at prescribers and patients as a labelling and safety update.

Key Takeaways

Mycophenolate mofetil (MMF)-containing products
Risk of pregnancy loss and congenital malformations
Post-treatment contraception extended from 6 weeks to 6 months
Applies to women of childbearing potential
Published by SAHPRA
South African Health Products Regulatory Authority (SAHPRA)